Fusion Conference's Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases

1–4 June 2018
Nassau, Bahamas

Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease, which affects over 5 million people in the US and over 35 million people worldwide. Currently, only four drugs are approved for alleviating symptoms in AD patients, and no new therapy has been approved for AD since 2003. Other related neurodegenerative diseases such as Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are also age-dependent and lack effective therapies. Hence, finding cures for AD and other related neurodegenerative diseases is urgent and various approaches should be actively pursued. This planed conference intends to bring leading scientists and clinicians from all over the world to present their unpublished observations or findings to attendees and to share their vision or prospects on translational research. We expect that some presenters, either by talks or posters, will discuss our current state of knowledge in disease mechanisms, novel targets or approaches for identifying new therapeutic targets, and biomarkers for diagnosis or treatment readouts. We will also invite speakers who are conducting later stages of drug discoveries, including presentations of clinical trial results. The talks and poster presentations will include the most updated therapeutic strategies, newly discovered therapeutic targets, and recent clinical developments at various stages in the area of Alzheimer’s and related neurodegenerative diseases.   Key topics of discussion will include: 1) BACE1 inhibitors and/or γ-secretase modulators for reducing amyloid deposition (BACE1 inhibitor trial results are expected to be in late phases at several companies like Merck and AstraZeneca); 2) active and passive vaccination for enhancing clearance of amyloid plaques; 3) vaccines for reducing tau pathology; 4) antisense approaches for AD, PD and ALS therapy; 5) neural stem cell approaches for neurodegeneration; and 6) Inflammatory modulators for neurodegeneration. The significance of having this conference is to provide a unique forum for the research community focusing on translational studies geared towards therapies in AD and related neurodegenerative diseases to come together and to discuss the latest advances and the future challenges in the field.  It will also facilitate interactions between junior scientists and leading investigators in a relatively small conference setting.